Huapont Life Sciences Co.,Ltd

002004

CNE000001JJ6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 17/07/2024 am IST			5-day change	1st Jan Change
3.84 ^CNY	+0.52%		+2.67%	-17.60%

02/07	Tranche Update on Huapont Life Sciences Co.,Ltd's Equity Buyback Plan announced on December 28, 2023.	CI
28/05	Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024	CI

Tranche Update on Huapont Life Sciences Co.,Ltd's Equity Buyback Plan announced on December 28, 2023.

July 03, 2024 at 01:09 am IST

From April 1, 2024 to June 30, 2024, the company has repurchased 2,280,000 shares, representing 0.12% for CNY 10.08 million. With this, the company has completed the repurchase of 5,785,808 shares, representing 0.29% for CNY 25.67 million under the buyback announced on December 28, 2023.

Latest news about Huapont Life Sciences Co.,Ltd

Tranche Update on Huapont Life Sciences Co.,Ltd's Equity Buyback Plan announced on December 28, 2023.	03/07	CI
Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024	29/05	CI
Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023	25/05	CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	26/04	CI
Tranche Update on Huapont Life Sciences Co.,Ltd's Equity Buyback Plan announced on December 28, 2023.	02/04	CI
Huapont Life Sciences Co.,Ltd announces an Equity Buyback for CNY 30 million worth of its shares.	27/12	CI
Huapont Life Sciences Co.,Ltd authorizes a Buyback Plan.	27/12	CI
Huapont Life Sciences Co.,Ltd(SZSE:002004) dropped from Shenzhen Stock Exchange Component A Share Index	11/12	CI
Huapont Life Sciences Co.,Ltd(SZSE:002004) dropped from Shenzhen Stock Exchange Component Index	11/12	CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023	09/23/09	CI
Huapont Life Sciences Co.,Ltd Approves Final Cash Dividend Per 10 Shares for 2022	19/23/19	CI
Huapont Life Sciences Co.,Ltd Proposes Final Cash Dividend for the Year 2022	28/23/28	CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	26/23/26	CI
Huapont Life Sciences Forms 100 Million Yuan Drug Research, Information Sharing Center	10/23/10	MT
Huapont Life Sciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/22/30	CI
Huapont Life Sciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	18/22/18	CI
Huapont Life Sciences Co., Ltd. Announces Dividend on A Shares for the Year 2021, Payable on June 2, 2022	28/22/28	CI
Huapont Life Sciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/22/29	CI
Huapont Life Sciences Co., Ltd. Approves Profit Distribution for 2021	14/22/14	CI
Huapont Life Sciences Maintains Final 2021 Dividend as Full-Year Profit Rises 2.8%	22/22/22	MT
Huapont Life Sciences Co., Ltd. Proposes Final Cash Dividend for 2021	22/22/22	CI

Chart Huapont Life Sciences Co.,Ltd

Duration

Period

More charts

Company Profile

HUAPONT LIFE SCIENCES CO., LTD. is a China-based company principally engaged in the research and development, manufacture and sales of pesticide chemical products. The Company operates through three segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sales of skin pharmaceuticals, antituberculous pharmaceuticals and other manufactured products. Its products include fleroxacin and ambroxol hydrochloride for injection, and lecithin-bound iodine capsules, among others. The Pesticide Chemical segment is engaged in the production and sales of pesticides and other fine chemicals, including herbicides, bactericides and insecticides, among others. The Bulk Drug segment is engaged in the research and development and manufacture of bulk drugs and medical intermediates. The Company is also engaged in the provision of travel services, the sales of tea and the provision of technical services, among others.

Sector

Pharmaceuticals

Calendar

31/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUAPONT LIFE SCIENCES CO.,LTD	-17.60%	1.04B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B